pharmaphorum25m
Australia joins EU in turning down Alzheimer's drug Leqembi
The regulator joins the EU regulator in refusing to register Leqembi, which gave similar reasons for its position on the drug ...
pharmaphorum2h
NIH study backs Bavarian Nordic mpox jab for adolescents
An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in ...
JCN Newswire2h
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
Eisai will request a reconsideration of this decision under Section 60* of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in Australia.
Eisai will request reconsideration of initial decision for lecanemab in Australia
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...
Biogen (BIIB): Pioneering CNS Treatments and Future Growth Prospects
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...